Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

914
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
914
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

3.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.1K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placenta Praevia and Placenta Accreta Spectrum: Diagnosis and Management: Green-Top Guideline No. 27a.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Temperature stress-induced production of salicylic acid from endophytic <i>Aspergillus flavus</i> with its <i>in silico</i> and <i>in vitro</i> anti-inflammatory potential and promising effect in combination with ibuprofen.

Frontiers in microbiology·2026
Same author

The phytochemical analysis of <i>Carissa macrocarpa</i>, cytotoxic potential of fractions, and the molecular modulation on p53 expression in HT-29 and LS174T cell lines.

Artificial cells, nanomedicine, and biotechnology·2026
Same author

Cytotoxicity and antibacterial BioEffects of CuO-Zn nanoparticles synthesized from Lactobacillus helveticus yogurt isolates targeting RsbA gene expression.

Scientific reports·2026
Same author

Effect of stinging nettle powder (Urtica dioica) supplementation on productive and physiological performance of laying hens.

Tropical animal health and production·2026
Same author

Fungal-mediated green synthesis of ZnO-MnO nanocomposites with antimicrobial and anticancer properties.

Scientific reports·2026
Same journal

TRPC5 as a Modulator of TRPV1 Signalling in Pathological Pain States.

Neuropharmacology·2026
Same journal

Loss of mGlu<sub>5</sub> receptors from PV inhibitory neurons attenuates sex differences in ethanol and sucrose seeking.

Neuropharmacology·2026
Same journal

PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain.

Neuropharmacology·2026
Same journal

Purinergic-cytokine signaling as a regulatory axis in neuroimmune development.

Neuropharmacology·2026
Same journal

Acupuncture Improves Depressive Symptoms and Prefrontal Cortical Function in Mild to Moderate Depressive Disorder: A Randomized Sham-Controlled Trial and fNIRS study.

Neuropharmacology·2026
Same journal

A staged zebrafish-mouse screening strategy for antiseizure compound prioritization.

Neuropharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity
06:11

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity

Published on: September 26, 2025

1.3K

Optimizing cognitive enhancement through dopamine transporter modulation.

Marco Niello1, Predrag Kalaba2, Anita Cybulska-Klosowicz3

  • 1Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, 1090, Austria; Genetics of Cognition Laboratory, Neuroscience Area, Istituto Italiano di Tecnologia, via Morego, 30, Genova, 16163, Italy; IRCCS Azienda Ospedaliera Metropolitana (AOM) di Genova, Largo R. Benzi, 10, Genova, 16132, Italy.

Neuropharmacology
|April 14, 2026
PubMed
Summary
This summary is machine-generated.

New psychostimulants targeting the dopamine transporter (DAT) show promise for cognitive enhancement. By increasing DAT residence time, these compounds improve dopamine signaling and cognitive flexibility, offering safer therapeutic potential.

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.7K

Related Experiment Videos

Last Updated: Apr 16, 2026

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity
06:11

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity

Published on: September 26, 2025

1.3K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.7K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Psychostimulants modulate dopamine transporter (DAT) activity, influencing cognition and behavior.
  • Clinical use of traditional psychostimulants is limited by abuse potential and side effects.
  • R-modafinil analogs offer potential for cognitive enhancement with reduced addiction liability.

Purpose of the Study:

  • To investigate if R-modafinil analogs with extended dopamine transporter (DAT) residence time enhance cognitive function.
  • To explore the relationship between DAT binding kinetics and psychostimulant efficacy.

Main Methods:

  • In vitro equilibrium and non-equilibrium binding assays to determine DAT residence time.
  • In vivo fast-scan cyclic voltammetry to measure dopamine signaling.
  • Cognitive assays in healthy and scopolamine-treated rats to assess cognitive flexibility.

Main Results:

  • Prolonged DAT occupancy by R-modafinil analogs enhanced dopamine signaling.
  • Compounds with longer DAT residence times, like S-MK-26 and (S,S)-CE-158, produced significant improvements in cognitive flexibility.
  • These effects were observed in both healthy and cognitively impaired rat models.

Conclusions:

  • DAT binding kinetics are crucial in determining the behavioral effects of psychostimulants.
  • Developing DAT ligands with slow off-rates offers a promising strategy for safer, more effective cognitive enhancers.
  • This research supports the development of novel dopamine-based therapeutics for cognitive disorders.